ArticleFrontiers in oncology2026
Knowledge, attitudes, and practices toward chemotherapy resistance among oncologists: a multinational cross-sectional study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study assessed oncologists' knowledge, attitudes, and practices regarding chemotherapy resistance across multiple countries. Methods: A cross-sectional study was conducted from September 2023 to February 2024 using a structured questionnaire adapted from previous literature and translated into French, Russian, and Chinese. Data were analyzed using SPSS. Independent t-tests, ANOVA, and multivariable logistic regression were used to examine associations between demographic characteristics and knowledge, attitude, and practice scores. Results: A total of 3,779 oncologists participated, with a mean age of 36.92 ± 9.24 years; 53.1% were female. Most participants were medical oncologists (50.0%), followed by clinical oncologists (23.4%) and radiation oncologists (18.8%). Nearly half had 0-9 years of professional practice, and the largest proportion were from Iraq (21.4%). In multivariable analysis, oncologists aged ≥56 years had lower odds of good knowledge (OR = 0.76, 95% CI: 0.58-0.98, p = 0.04). Female participants showed higher odds of good knowledge (OR = 1.22, 95% CI: 1.02-1.46, p = 0.03) and positive attitudes (OR = 1.20, 95% CI: 0.99-1.45, p = 0.04) than males. Post-doctorate holders also had greater odds of good knowledge (OR = 1.57, 95% CI: 1.25-1.97, p = 0.01) and positive attitudes (OR = 1.50, 95% CI: 1.20-1.87, p = 0.01) compared with those holding a medical bachelor's degree. Longer professional experience, ≥10 years in the cancer field, and previous exposure to chemotherapy resistance cases were also associated with better knowledge and more positive attitudes. Conclusion: The findings highlight important gaps in oncologists' knowledge and practices regarding chemotherapy resistance. Targeted educational programs and continuous professional development, particularly in underrepresented regions, may help strengthen clinical preparedness and improve chemotherapy resistance management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.